{"type":"trials","record":{"id":32063,"source_id":"clinicaltrials-gov","external_id":"NCT06130787","title":"Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy","brief_summary":"French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"University Hospital, Clermont-Ferrand","enrollment":321,"countries":["France"],"start_date":"2023-11-17","completion_date":"2028-11-17","last_update_date":"2024-09-27","source_url":"https://clinicaltrials.gov/study/NCT06130787","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:23.954312+00:00","last_seen_at":"2026-09-25T06:15:13.984+00:00","metadata":{"sex":"ALL","acronym":"BIO-TIMER","age_range":"18 Years","comparator":null,"organization":"University Hospital, Clermont-Ferrand","interventions":["Blood and bone marrow sample"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Biological age determination — Day 0;Month 3;Month 12","Individual fragility assessment — Day 0;Month 6;Month 12;Month 24;Month 36","Tolerance of tyrosine kinase inhibitors — Day 0;Month 3;Month 6;Month 12;Month 24;Month 36","Distribution of individual clinical fragility levels assessed by Geriatric Core Data set at the time of diagnosis. — Da…","Distribution of individual clinical fragility levels assessed by Rockwood clinical frailty score at the time of diagnos…","Evaluation of therapeutic response through quantification of the BCR::ABL transcript — Month 3;Month 6;Month 12;Month 1…","Assessment of therapeutic response by quantification of residual disease — Month 3;Month 6;Month 12;Month 15;Month 18;M…","Assessment of patients' quality of life — Day 0;Month 6;Month 12;Month 24;Month 36"],"design_description":"NA · SINGLE GROUP · OTHER · NONE","source_has_results":false},"controlled_terms":["Leukemia,Myeloid, Chronic","Blood and bone marrow sample"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: biological age.","quality_checked_at":"2026-09-25T06:15:15.562724+00:00","duplicate_cluster_key":"id:nct06130787","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-11-17 to 2028-11-17","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:14.005Z","intervention":["Blood and bone marrow sample"],"participants":321,"study_design":"NA · SINGLE GROUP · OTHER · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Biological age determination — Day 0;Month 3;Month 12","Individual fragility assessment — Day 0;Month 6;Month 12;Month 24;Month 36","Tolerance of tyrosine kinase inhibitors — Day 0;Month 3;Month 6;Month 12;Month 24;Month 36","Distribution of individual clinical fragility levels assessed by Geriatric Core Data set at the time of diagnosis. — Da…","Distribution of individual clinical fragility levels assessed by Rockwood clinical frailty score at the time of diagnos…","Evaluation of therapeutic response through quantification of the BCR::ABL transcript — Month 3;Month 6;Month 12;Month 1…","Assessment of therapeutic response by quantification of residual disease — Month 3;Month 6;Month 12;Month 15;Month 18;M…","Assessment of patients' quality of life — Day 0;Month 6;Month 12;Month 24;Month 36"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"biological-age-biomarkers","is_published":true,"match_reasons":["Title contains controlled term: biological age.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Biological age biomarkers","slug":"biological-age-biomarkers"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/32063","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}